---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-006745"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:08:23.414243+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance

## Summary
- FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).
- Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.
- FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.
- FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.
- Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG.

## SEC filing metadata
- accession: 0001140361-25-006745
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/0001140361-25-006745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125006745/ef20044777_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-006745
- JSON: https://secwatch.observer/filing/0001140361-25-006745.json
- Plain text: https://secwatch.observer/filing/0001140361-25-006745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.